Imaging Histone Deacetylase in the Heart

ConditionsHeart Failure With Normal Ejection Fraction Left Ventricular Hypertrophy Aortic Valve Stenosis Diabetes

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-85

SponsorMassachusetts General Hospital

About this trial

The overall goal of this PET-MR imaging trial is to evaluate 11C-Martinostat, a histone deacetylase targeted radioligand, in patients with aortic stenosis, individuals with diabetes, and healthy volunteers.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Healthy adults with no known history of medical disease

Age 18-85 years

No history cardiovascular disease

Ability to provide informed consent

Disqualifiers

Known contraindication to MRI

Trial design

Design model

Parallel

Treatments tested in this trial

11C-Martinostat
Drug
Imaging probe for evaluating the activity of histone deacetylase in the heart
PET-MRI
Device
Siemens PET-MR Scanner (Biograph MMR)

Treatment groups

96 Participants

are divided into 3 treatment groups

Group A: Healthy SubjectsActive comparator 2 interventions

Group B: Diabetes Patient SubjectsActive comparator 2 interventions

Group C: Aortic Stenosis Patient SubjectsExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

11C-Martinostat Binding

Comparison of regional HDAC activity as measured by standard uptake value ratio (SUVR) of 11C-Martinostat between patient subjects with aortic stenosis or diabetes and healthy volunteers

Time frame

10-60 minutes post-injection

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Massachusetts General Hospital

Lead sponsor

Source ClinicalTrials.gov

Apply now